For the year ending 2025-12-31, PDSB had -$14,977,622 decrease in cash & cash equivalents over the period. -$27,752,012 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total operating expenses | 31,543,959 |
| Interest income | 1,217,241 |
| Interest expense | 5,338,607 |
| Benefit for income taxes | -1,169,820 |
| Net loss | -34,495,505 |
| Stock-based compensation expense | 4,106,606 |
| Issuance of shares in consulting agreements | 298,501 |
| Amortization of debt discount | 1,553,835 |
| Loss on retirement of debt | -1,107,004 |
| Depreciation expense | 21,836 |
| Finance lease amortization expense | 38,682 |
| Prepaid expenses and other current assets | 173,564 |
| Accounts payable | 1,889,580 |
| Accrued expenses | -2,098,987 |
| Operating lease liabilities | 0 |
| Net cash used in operating activities | -27,752,012 |
| Purchase of equipment | 0 |
| Net cash used in investing activities | 0 |
| Proceeds from issuance of pre-funded warrants | 1,038,094 |
| Proceeds from issuance of warrants | 5,315,811 |
| Proceeds from exercise of pre-funded warrants | 100 |
| Proceeds from exercise of stock options | 0 |
| Payments of finance lease obligations | 61,119 |
| Loan principal payments | 6,666,667 |
| Loan repayment | 19,000,000 |
| Net proceeds from issuance of loan | 18,164,795 |
| Proceeds from issuance of common stock, net of issuance costs | 9,709,064 |
| Proceeds from issuance of common stock from at-the-market program, net of issuance costs | 4,274,312 |
| Net cash provided by financing activities | 12,774,390 |
| Net (decrease) increase in cash and cash equivalents | -14,977,622 |
| Cash and cash equivalents at beginning of period | 41,689,591 |
| Cash and cash equivalents at end of period | 26,711,969 |
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)